Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.49 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.49 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729495 | 1.00 | THRB (0.61) | THRBATMPTGS2PTGS1PDE3A | |
| SCHEMBL5729672 | 0.83 | PTGS2 (0.70) | PTGS2PTGS1PDE3A | |
| SCHEMBL12473720 | 0.80 | THRB (0.89) | THRBATMPTGS2HDAC3HDAC4 | |
| SCHEMBL7967988 | 0.80 | THRB (0.89) | THRBATMPTGS2HDAC3HDAC4 | |
| SCHEMBL7967986 | 0.80 | THRB (0.89) | THRBATMPTGS2HDAC3HDAC4 | |
| SCHEMBL5731027 | 0.79 | PTGS2 (0.60) | PTGS2PTGS1PDE3AESR1 | |
| SCHEMBL5730530 | 0.79 | PTGS2 (0.60) | PTGS2PTGS1PDE3AESR1 | |
| SCHEMBL25990192 | 0.79 | IP6K1 (0.78) | THRBATMIP6K1IP6K3IP6K2 | |
| 4-Methoxycinnamic Acid SCHEMBL58700 | 0.78 | THRB (1.00) | THRBATMPTGS2HDAC3HDAC4 | |
| 4-Methoxycinnamic Acid SCHEMBL12473722 | 0.78 | THRB (1.00) | THRBATMPTGS2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1102755-A1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008001-A1 | SUBSTITUTED ISOXAZOLE AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | THRB 394/4885ATM 820/4885PTGS2 728/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | THRB 394/4885ATM 820/4885PTGS2 728/4885 |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | THRB 697/4885ATM 499/4885PTGS2 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.